CS014
Idiopathic Pulmonary Fibrosis (IPF) / Pulmonary Hypertension-ILD (PH-ILD)
Phase IActive; Phase I completed, advancing to Phase II
Key Facts
Indication
Idiopathic Pulmonary Fibrosis (IPF) / Pulmonary Hypertension-ILD (PH-ILD)
Phase
Phase I
Status
Active; Phase I completed, advancing to Phase II
Company
About Cereno Scientific
Cereno Scientific is a clinical-stage biotech focused on developing first-in-class, disease-modifying treatments for rare cardiovascular and pulmonary diseases with high unmet need. The company's strategy leverages orphan drug designations and accelerated pathways to efficiently advance its dual-platform pipeline, led by Phase II candidate CS1 for Pulmonary Arterial Hypertension (PAH). With a Phase II asset, a Phase I candidate, and a preclinical program, Cereno is positioned for value inflection through clinical milestones and potential partnerships.
View full company profile